UKINETS2023 Oral Communications Section (3 abstracts)
Interim analysis of Lantana: A phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours (NCT05178693)
Karolina Rzeniewicz 1 , Caroline Ward 1 , Sairah Khan 2 , Mitesh Naik 2 , Tara Barwick 2 , Eric Aboayge 1 & Rohini Sharma 1
1Imperial College, London, United Kingdom; 2Imperial College NHS Healthcare Trust, London, United Kingdom
Background: Peptide-receptor-radionuclide-therapy (PRRT) improves progression free survival in metastatic neuroendocrine neoplasia (NEN). To be suitable for PRRT, somatostatin receptor-2 (SSTR2) must be present on tumour site as determined by positive uptake on [68Ga]Ga-DOTA-peptide-PET/CT. LANTana is an ongoing study evaluating whether treatment with the demethylating agent, ASTX727, results in re-expression of SSTR2, as determined by [68Ga]Ga-DOTA-peptide-PET/CT, allowing subsequent PRRT.
Methods: Key eligibility criteria: histological diagnosis of NEN (Ki67<55%). No/low uptake on baseline [68Ga]Ga-DOTA-TATE-PET/CT
Design: Following baseline [68Ga]Ga-DOTA-peptide-PET/CT, patients receive 5 days of ASTX727 (fixed dose 35mg decitabine + 100mg cedazuridine). [68Ga]Ga-DOTA-peptide-PET/CT is repeated on day 8+2. If there is significant uptake as defined as greater-than-liver-in-most-lesions, patients will receive up to further 4 cycles of ASTX727 on days 1-5 followed by PRRT on day 8+2.
Results: As of 06/09/2023 10 patients were enrolled. Most common primary site was lung (n=5), and median Ki67 was 20% (range 1%-39%). Patients had received a median of two prior systemic treatments (range 1-4). 2 patients withdrew consent prior to repeat [68Ga]Ga-DOTA-peptide-PET/CT. Four patients had re-expression of SSTR2 as illustrated by increase expression on [68Ga]Ga-DOTA-peptide-PET/CT following ASTX727, two of whom proceeded to PRRT. Following administration of ASTX727, 28 grade 1 or 2 adverse events (AEs) occurred in four patients, the commonest being nausea. One episode of grade 3 neutropenic sepsis was recorded. No patient discontinued ASTX727 due to AEs.
Conclusion: Use of a demethylating agent to re-express SSTR2 is feasible allowing PRRT in patients who otherwise would not be eligible. The safety profile was manageable, with no unexpected toxicities. The study is ongoing.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more